Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. - Wikidata - wikimedia - TriplyDB

Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.

Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.

http://www.wikidata.org/entity/Q34421642

about

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.Fingolimod for relapsing multiple sclerosis: an update.FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value.Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod.FTY720 (fingolimod) for relapsing multiple sclerosis.Modulators of the Sphingosine 1-phosphate receptor 1.Sphingosine 1-phosphate receptor 1 agonists: a patent review (2013-2015).

P2860

Q33881977-494E8C44-2C9F-40B5-902B-2DD721BC8E01 Q34618474-33993E4F-BC58-413D-8B17-A545639B479C Q35876398-982EC00E-E653-4310-91EC-59354839DD7B Q36891556-086C01DD-7F2E-4778-94E3-D13A40E64F77 Q37154788-4D042650-E6BC-4D22-BDE4-71C98D98FC34 Q38152543-BCB09EEE-EE8E-4EB1-B308-B7162FD6C4EB Q38762603-D5DAAA26-9CC2-488B-AA95-FE6F59DE7814

P2860

Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.

http://www.wikidata.org/entity/Q34421642

description

2005 nî lūn-bûn

@nan

2005 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.

@ast

Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.

@en

Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.

@nl

type

label

Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.

@ast

Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.

@en

Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.

@nl

prefLabel

Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.

@ast

Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.

@en

Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.

@nl

P1433

Q34421642-83D5C5FE-86DF-4DC8-A193-88A5FF60DBED

P1476

Q34421642-030570C3-459B-4FD0-8C3C-8E1AF41CC14A

P2093

Q34421642-19359244-5F47-4D4E-BD8C-C4C403913483

Q34421642-2FCC325D-8177-46E7-80FA-F401840BA490

Q34421642-33C0B4FA-506B-4724-908E-3551C9DD92FD

Q34421642-4391E2E4-85B0-49C2-86E5-DCB2DE1ED431

Q34421642-4E652492-1FC5-4BD0-A491-A6209711490F

Q34421642-5E4D5403-BCEA-44E1-AA25-0AEE7E40B2D2

Q34421642-B599C290-E17F-4BC6-9F2A-32C6A374D64E

Q34421642-E1FF04E0-8B90-46FD-97B7-E532DE1B0F97

P2860

Q34421642-07F087B9-A889-4908-B33F-1EDF8CF786D0

Q34421642-2B4D3E30-C5EB-4E48-8F66-85C105FF647C

Q34421642-2C12A39C-69C5-413F-9FD6-9240613BE2D7

Q34421642-2C86F67C-A770-4B32-883A-A3D5DBE8F7C3

Q34421642-39CD41EF-2D84-4DC0-B8ED-2AAF13CE610C

Q34421642-5CAD18DC-D887-42EC-9F93-3E83175357A6

Q34421642-6CEF9BF5-165A-46C9-B13A-0EC1DAA2F7F8

Q34421642-8AC7CB39-818B-41CF-A327-FA26FA400CA8

Q34421642-986678EA-8664-4443-AC39-C390919B7E8F

Q34421642-9BDDB784-45EE-40BC-BEE6-C57DBA135924

P304

Q34421642-8530155F-1F37-4094-A104-EB50D986DA8F

P31

Q34421642-4C08FA73-D8E3-4862-8392-708CCC93214E

P356

Q34421642-998271CD-F8FF-4B44-83B9-724B293FDF19

P407

Q34421642-3037AC7D-97D2-4ECC-80F1-3111E8B2CA2C

P433

Q34421642-1A0AAD08-8EB4-4E0A-A173-2302E6DBB420

P478

Q34421642-0B5ACCEF-B1AD-42EB-AE39-28BC0E83823D

P577

Q34421642-A9BBAA90-5903-4C97-8B8D-0D5DC578FE89

P698

Q34421642-123591FE-AC66-4FD9-A847-4EB0679FE8E6

P356

S0100-879X2005000500005

P1433

Brazilian Journal of Medical and Biological Research

P1476

Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.

@en

P2093

A Skerjanec

http://www.w3.org/2001/XMLSchema#string

C R Felipe

http://www.w3.org/2001/XMLSchema#string

H Tedesco-Silva Jr

http://www.w3.org/2001/XMLSchema#string

J O Medina-Pestana

http://www.w3.org/2001/XMLSchema#string

P G Machado

http://www.w3.org/2001/XMLSchema#string

R Garcia

http://www.w3.org/2001/XMLSchema#string

R Schmouder

http://www.w3.org/2001/XMLSchema#string

S I Park

http://www.w3.org/2001/XMLSchema#string

P2860

Cell type-specific localization of human cardiac S1P receptors

Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

Mycophenolate mofetil and its mechanisms of action.

FTY720: altered lymphocyte traffic results in allograft protection.

Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols.

Synthesis and biological evaluation of 2,2-disubstituted 2-aminoethanols: analogues of FTY720.

Egress: a receptor-regulated step in lymphocyte trafficking.

The immune modulator FTY720 targets sphingosine 1-phosphate receptors.

Prolongation of canine liver allograft survival by a novel immunosuppressant, FTY720: effect of monotherapy and combined treatment with conventional drugs.

P304

683-694

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1590/S0100-879X2005000500005

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P577

2005-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15917949

http://www.w3.org/2001/XMLSchema#string